GSK has agreed to a $2.2 billion settlement to resolve the majority of U.S. state court Zantac lawsuits, with an additional ...

We recently published an article titled Jim Cramer on Super Micro Computer and Other Stocks. In this article, we are going to ...

In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age ...

GSK paid $22.4 million on Sept. 27 for 2.8 million more shares of Wave Life Sciences for $8 each. GSK now owns 16.8 million ...

Taking full advantage of the stock market and investing with confidence ... Value investors should also note GSK's Price/Sales ratio of 2X. A company's earnings performance is important for ...

GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer ...

GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 ...

GSK plc (NYSE:GSK – Get Free Report) shares saw unusually-high trading volume on Wednesday . Approximately 10,740,675 shares changed hands during mid-day trading, an increase of 196% from the previous ...